Navigation Links
Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment
Date:6/15/2010

PHILADELPHIA Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

"Our results provide preclinical evidence for the rational combination of BRAF-targeted therapy and immunotherapy in the treatment of this most dangerous type of skin cancer," said lead researcher Jennifer A. Wargo, M.D., division of surgical oncology at Massachusetts General Hospital, Boston.

"By blocking the oncogenic BRAF, tumor antigen expression may be restored. This would make the melanoma tumors susceptible to strategies incorporating immunotherapy," she said.

Previous studies have shown that melanoma treatment with selective BRAF inhibitors are very effective and result in a high initial response rate, but the response is temporary. An alternative approach would be to combine other agents and extend the duration of treatment response.

Using biopsies of melanoma tumors, the researchers investigated the effects of mitogen-activated protein kinase (MAPK) pathway inhibition vs. selective inhibition of BRAF-V600E on T-cell function.

Inhibition of the MAPK pathway with a specific inhibitor of BRAF-V600E resulted in increased expression of antigens, which was associated with improved recognition by antigen-specific T-cell. T-cell function was not compromised after treatment with BRAF-V600E.

Mario Colombo, Ph.D., director of molecular immunology at the Italian National Cancer Institute and senior editor for Cancer Research, said these results advance cancer research by offering new arguments to sustain the combination of selective targeted therapy with immunotherapy.

"This study shows the need for considering the effect of off-targeted drug therapy on the many aspects of host immune response to make real the combination of chemo- and immunotherapy," Colombo said. "It also prompts the idea of performing vaccination in the attempt to eradicate the disease and prevent recurrence."

Several clinical trials are underway using agents that selectively inhibit BRAF-V600E in patients with metastatic melanoma. These studies have shown impressive response rates, though durability of response remains an issue, according to Wargo.

Results of this study provide a basis for combining this type of therapy with immunotherapy, with the goal of improving durability of responses.


'/>"/>

Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert  

Related medicine news :

1. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
2. New Laser Technology Combined with Manual Physical Therapy Offer Pain Relief to Chronic Pain Sufferers
3. Singapore Performs Asia's First Combined Heart and Liver Transplant
4. Promega Maxwell 16 IVD System CE Marked to the European Union IVD Directive Delivers Combined Solution for Infectious Disease
5. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
6. Combined drug therapy to treat TB and HIV significantly improves survival
7. Combined mammography and breast MRI useful for some high-risk women
8. Green tea chemical combined with another may hold promise for treatment of brain disorders
9. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
10. Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments
11. FDA Approval of new Prostate Treatment Shows Promise of Cancer Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice Treatment Center® ... March 13-16, was a busy spot this year. Liz Solovay and Adrian Picheny, ... preventing outbreaks among camp communities during the upcoming 2017 camping season. “Lice infestations ...
(Date:3/28/2017)... ... ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in women's ... loss. Although hair transplant procedures can be seen as more of a man’s issue, ... two reasons a woman may see her hair thinning. , “We are used to ...
(Date:3/28/2017)... ... , ... Thank you to all who attended Capio Partners Winter 2017 Healthcare ... exclusive to providers and offered an opportunity to collaborate and network with healthcare colleagues ... Hyatt where attendees gathered for a lively discussion on trends and issues that healthcare ...
(Date:3/28/2017)... ... 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s ... things that his parents and teachers had asked of him that he had neglected to ... to defy the Almighty Creator. There were some who would have felt themselves to be ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/27/2017)... 2017 Summary This report ... Lilly and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)... IRVINE, Calif. , March 27, 2017  Cryoport, ... announced that it intends to offer shares of common ... shelf registration statement on file with the Securities and ... market and other conditions, and there can be no ... be completed, or as to the actual size or ...
Breaking Medicine Technology: